Your Health, We Care
Pacritinib is indicated for the treatment of adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis and a platelet count of less than 50 × 10⁹/L.
This indication was granted accelerated approval based on the reduction in spleen volume. Continued approval of this indication may be contingent upon the verification and description of its clinical benefit in confirmatory trials.
FDA，2025.10
It is indicated for the treatment of adult patients with intermediate- or high-risk primary or secondary myelofibrosis and a platelet count of less than 50 × 10⁹/L.【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：0
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
